Too much sorbitol may raise fatty liver disease risk, study finds
Excessive intake of sorbitol, a type of sugar naturally found in many fruits and used as a sugar substitute, may increase the risk of metabolic…
News
Nebokitug reduces immune cell activity that drives PSC: Data
Nebokitug, an experimental infusion therapy being developed by Chemomab Therapeutics for primary sclerosing cholangitis (PSC), reduces the inflammatory…
New biomarkers may help detect pregnancy-linked liver complication
Levels of the metabolite palmitic acid and the protein ACSL1 in the bloodstream can accurately detect the presence and severity of intrahepatic cholestasis of…
Belapectin may help reduce liver scarring in those with severe MASH
Galectin Therapeutics‘ experimental medication belapectin may help reduce liver scarring, or fibrosis, and lower the risk of blood vessel complications in people with metabolic-associated…
Stem cell therapy may boost liver health in infants with biliary atresia
Therapy using stem cells derived from donor umbilical cords may help improve outcomes in infants with biliary atresia who have undergone standard Kasai surgery,…
Model predicts combo therapy may cure hepatitis C in 2 months
New modeling data predict that bemnifosbuvir and ruzasvir, an experimental combination treatment being developed by Atea Pharmaceuticals for chronic hepatitis C, may…
New trial testing probiotic for reducing liver inflammation in PSC
Liscure Biosciences has launched a Phase 2 clinical trial to test whether its experimental probiotic LB-P8 can improve gut health and reduce liver inflammation…
Melatonin may protect the liver from cholestasis-related injury
Treatment with melatonin, a naturally occurring hormone best known for regulating sleep, may help reduce liver injury caused by cholestasis, according to a study…
Rezdiffra reduces liver scarring in high-risk MASH patients: Trial data
Long-term treatment with Rezdiffra (resmetirom) reduces liver scarring and other signs of advanced disease in adults with high-risk compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis…
Used in Alagille mice, ASO therapy found to improve liver function
An experimental antisense oligonucleotide (ASO) therapy designed to boost production of the Jagged-1 protein — which is known as Jag1 in mice and JAG1 in…
Recent Posts
- An easy transition to new vitamins is a breakthrough for my son
- Too much sorbitol may raise fatty liver disease risk, study finds
- Nebokitug reduces immune cell activity that drives PSC: Data
- New biomarkers may help detect pregnancy-linked liver complication
- Access to food is a survival tactic when your liver needs nutrition